Navigation

DEA No. 1605

DEA No. 1605 - General Information

Tricyclic anorexigenic agent unrelated to and less toxic than amphetamine, but with some similar side effects. It inhibits uptake of catecholamines and blocks the binding of cocaine to the dopamine uptake transporter. [PubChem]

 

Pharmacology of DEA No. 1605

DEA No. 1605 is a sympathomimetic amine, which is similar to an amphetamine. DEA No. 1605 stimulates the central nervous system (nerves and brain), which increases your heart rate and blood pressure and decreases your appetite. Sympathomimetic appetite suppressants are used in the short-term treatment of obesity. Their appetite-reducing effect tends to decrease after a few weeks. Because of this, these medicines are useful only during the first few weeks of a weight-loss program.

 

DEA No. 1605 for patients

Use caution when driving, operating machinery, or performing other hazardous activities. Mazindol may cause dizziness, blurred vision, or restlessness, and it may hide the symptoms of extreme tiredness. If you experience these effects, avoid hazardous activities. Mazindol is habit forming. You can become physically and psychologically dependent on this medication, and withdrawal effects may occur if you stop taking it suddenly after several weeks of continuous use. Talk to your doctor about stopping this medication gradually.

 

DEA No. 1605 Interactions

You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. Changes in insulin and other diabetes drug therapies may be necessary during treatment with mazindol.Mazindol may reduce the effects of guanethidine (Ismelin). This could lead to an increase in blood pressure. Tell your doctor if you are taking guanethidine. Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). These drugs may decrease the effects of mazindol.

 

DEA No. 1605 Contraindications

Contraindicated in heart disease or high blood pressure, arteriosclerosis, and glaucoma.

 

Additional information about DEA No. 1605

DEA No. 1605 Indication: Used in short-term (a few weeks) treatment of exogenous obesity in conjunction with a regimen of weight reduction based on caloric restriction, exercise, and behavior modification in patients with a body mass index of 30 kg of body weight per height in meters squared (kg/m2) or in patients with a body mass index of 27 kg/m2 in the presence of risk factors such as hypertension, diabetes, or hyperlipidemia.
Mechanism Of Action: Although the mechanism of action of the sympathomimetics in the treatment of obesity is not fully known, these medications have pharmacological effects similar to those of amphetamines. Unlike other sympathomimetic appetite suppressants such as phentermine, mazindol is thought to inhibit the reuptake of norepinephrine rather than to cause its release.
Drug Interactions: Acetophenazine Decreased anorexic effect, may increase psychotic symptoms
Chlorpromazine Decreased anorexic effect, may increase psychotic symptoms
Ethopropazine Decreased anorexic effect, may increase psychotic symptoms
Fluphenazine Decreased anorexic effect, may increase psychotic symptoms
Methotrimeprazine Decreased anorexic effect, may increase psychotic symptoms
Mesoridazine Decreased anorexic effect, may increase psychotic symptoms
Methdilazine Decreased anorexic effect, may increase psychotic symptoms
Propericiazine Decreased anorexic effect, may increase psychotic symptoms
Perphenazine Decreased anorexic effect, may increase psychotic symptoms
Prochlorperazine Decreased anorexic effect, may increase psychotic symptoms
Trimeprazine Decreased anorexic effect, may increase psychotic symptoms
Triflupromazine Decreased anorexic effect, may increase psychotic symptoms
Trifluoperazine Decreased anorexic effect, may increase psychotic symptoms
Promazine Decreased anorexic effect, may increase psychotic symptoms
Promethazine Decreased anorexic effect, may increase psychotic symptoms
Propiomazine Decreased anorexic effect, may increase psychotic symptoms
Thiethylperazine Decreased anorexic effect, may increase psychotic symptoms
Thioridazine Decreased anorexic effect, may increase psychotic symptoms
Venlafaxine Risk of serotoninergic syndrome
Fluvoxamine Risk of serotoninergic syndrome
Fluoxetine Risk of serotoninergic syndrome
Guanethidine The agent decreases the effect of guanethidine
Paroxetine Risk of serotoninergic syndrome
Isocarboxazid Possible hypertensive crisis
Phenelzine Possible hypertensive crisis
Rasagiline Possible hypertensive crisis
Tranylcypromine Possible hypertensive crisis
Food Interactions: May be taken without regard to meals, but preferably 1 hour before a meal.
If product causes GI problems, it can be taken during meals.
Generic Name: Mazindol
Synonyms: Not Available
Drug Category: Adrenergic Uptake Inhibitors; Central Nervous System Stimulants; Dopamine Uptake Inhibitors
Drug Type: Small Molecule; Approved

Other Brand Names containing Mazindol: DEA No. 1605; Dimagrir; Magrilon; Mazanor; Mazildene; Mazindol [USAN-BAN-INN]; Mazindolum [INN-Latin]; Sanorex; Terenac; Teronac;
Absorption: Not Available
Toxicity (Overdose): Symptoms of a mazindol overdose include restlessness, tremor, rapid breathing, confusion, hallucinations, panic, aggressiveness, nausea, vomiting, diarrhea, an irregular heartbeat, and seizures.
Protein Binding: Not Available
Biotransformation: Hepatic.
Half Life: 10-13 hours
Dosage Forms of DEA No. 1605: Not Available
Chemical IUPAC Name: 5-(4-chlorophenyl)-2,3-dihydroimidazo[1,2-b]isoindol-5-ol
Chemical Formula: C16H13ClN2O
Mazindol on Wikipedia: https://en.wikipedia.org/wiki/Mazindol
Organisms Affected: Humans and other mammals